Day: October 13, 2021

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/ TORONTO, Oct. 13, 2021 (GLOBE NEWSWIRE) — Firm Capital Mortgage Investment Corporation (the “Corporation”) (TSX: FC) is pleased to announce that it has increased the size of its previously announced bought deal offering from $22,007,700 to $25,007,400. Pursuant to the amended terms, the Corporation, along with Eli Dadouch, Jonathan Mair and Michael Warner (the “Selling Shareholders”), have entered into an agreement (the “Agreement”) to sell, on a bought deal basis, to a syndicate of underwriters bookrun by TD Securities Inc., National Bank Financial Inc. and CIBC Capital Markets, 1,684,000 common shares of the Corporation (the “Shares”) at a price of $14.85 per Share (the “Issue Price”). Under the Agreement, 1,214,000 Shares will be issued from...

Gig Harbor, Washington , Oct. 13, 2021 (GLOBE NEWSWIRE) — Harbor Custom Development, Inc. (Nasdaq: HCDI, HCDIP, HCDIW, HCDIZ) (“Harbor,” “Harbor Custom Homes®,” or the “Company”), an innovative and market leading real estate company involved in all aspects of the land development cycle, today announced that President and CEO, Sterling Griffin, will present Harbor’s corporate overview and business objectives at the 14th annual LD Micro Main Event being held on October 14, 2021. The LD Micro Main Event has become the preeminent convention for the most powerful people in the small-cap world. Since 2008, over 1,600 companies have presented to LD Micros community of analysts and investors. This year’s Main Event will take place in person on October 12-14th at the Luxe Sunset Bel Air. For those that cannot join in person, please visit...

Anti-TROP-2 ADC with a drug payload SN38 (a DNA polymerase inhibitor) (ESG-401) has received FDA authorization to begin clinical trials in the US.ESG-401 addresses a highly unmet need for the treatment of multiple solid tumors, including triple-negative breast cancer and urothelial carcinoma.SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) previously announced that its partner Escugen Biotechnology Co, Ltd. (“Escugen”) and Sorrento’s subsidiary Levena (Suzhou) Biopharma Co., Ltd. (“Levena”) had received an approval letter from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for its Application for Clinical Trial (Acceptance No. CXSL2101069) of Recombinant Humanized Anti-Trop2 Mab-SN38 Conjugate. Today Sorrento announces...

BOSTON, Oct. 13, 2021 (GLOBE NEWSWIRE) — DraftKings Inc. (Nasdaq: DKNG) announced today it has agreed to a deal with the National Hockey League to become an Official Sports Betting, Daily Fantasy Sports and iGaming Partner of the league in the United States. To complement the deal, DraftKings has also reached an agreement with Turner Sports, including Bleacher Report, to be the exclusive sportsbook and daily fantasy sports provider for their coverage of the NHL®. “The NHL has some of the most passionate fans in all of sports and we are delighted to be working with the league once again, while developing a rich and engaging viewership and content experience that matches this fanbases’ enthusiasm through our deal with Turner,” said Jason Robins, CEO, chairman and co-founder, DraftKings. “Over the years DraftKings has become a brand...

Mach7 Technologies announces the live clinical use of its Enterprise Imaging Solution at Martha Jefferson Hospital, a Sentara-Healthcare-owned nonprofit community hospital in Charlottesville, VA. SOUTH BURLINGTON, Vt., Oct. 13, 2021 (GLOBE NEWSWIRE) — Mach7 Technologies, a company specializing in innovative medical imaging and data management solutions for healthcare providers, formally announced the successful Go-Live of its Enterprise Imaging Solution at Sentara Martha Jefferson Hospital. Martha Jefferson Hospital, founded in 1903, is a multi-specialty 176-bed general medical and surgical hospital with an employee staff of over 1,600 and 365 affiliated physicians. This is the second major Go-Live announcement of Mach7 solutions as part of Sentara Healthcare’s Picture Archiving and Communication System (PACS) modernization project....

DOVER, DE, Oct. 13, 2021 (GLOBE NEWSWIRE) — Metatron (OTC Pink: MRNJ), a mobile and web technology pioneer having developed over 2,000 apps on iTunes and Google Play, is pleased to announce it has developed a web based NFT marketplace with the OpenSea platform called NofungusAmongus.com (NFAS). The Company expects mobile app versions to become available following our recently released crypto e-commerce app Ketobodz on Google Play App store. Sales volumes of non-fungible tokens (NFTs) surged to $10.7 billion in the third quarter of 2021, up more than eightfold from the previous quarter, according to data from market tracker DappRadar, as the frenzy for crypto assets reached new highs.  NFTs use blockchain to record the ownership of digital items such as images, videos, collectibles and even land in virtual worlds. “We are very...

Figure 1Feni Island prospects and current Adyton drilling area at KabangFigure 2

FLNG Hilli – Hedged part of TTF linked production for Q1 2022: Golar is pleased to announce that it has entered into swap arrangements to hedge part of its TTF price exposure for the incremental 0.2 MTPA train 3 production for Q1 2022 at a TTF price of $28/MMBtu. With TTF gas prices averaging $28/MMBtu during Q1 2022, the additional capacity utilization is expected to realize $21.2 million of Net Income to Golar for the quarter. This implies a gross tolling fee of $11.4/MMBtu for the incremental production. For each $1.00/MMBtu change in TTF, Net Income realized by Golar will increase (or decrease) by $0.4 million for unhedged volumes during Q1 2022. Golar is also realizing increased Net Income from the Brent link component of production from trains 1 and 2. Golar’s realized share of Net Income increases by $2.7m for every $1/bbl that...

PASADENA, CA, Oct. 13, 2021 (GLOBE NEWSWIRE) — Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced entry into a collaboration with the Netherlands Cancer Institute, Amsterdam (NKI) , one of the world’s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent cancer research center, to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations. The pre-clinical studies are directed by Professor René Bernards (NKI), a leader in using genome wide functional genetic techniques to identify effective drug combinations, new drug targets, and mechanisms of resistance to cancer drugs. Using this technology, prof. Bernards’ group...